[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"autoimmune\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:autoimmune":36},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,65,89,111,136,177],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":37,"overallStatus":52,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":57,"completionDateStruct":59,"leadSponsor":61,"locationsCount":64},"100656495","phase-1-a-study-of-c-car168-in-participants-with-progressive-multiple-sclerosis-100656495",false,"NCT07825389","C-CAR168, an Autologous Anti-CD20\u002FBCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy","Multi-center, Phase 1b\u002F2 Clinical Study of an Autologous Anti-CD20\u002FBCMA Chimeric Antigen Receptor T-Cell Therapy (C-CAR168) for the Treatment of Progressive Multiple Sclerosis Refractory to Standard Therapy","Key Inclusion Criteria:\n\n* Able to sign and date the informed consent form.\n* Male or female, 18-55 years of age, body weight \\>=40 kg.\n* Diagnosis of MS according to the 2024 McDonald criteria with cohort-specific progressive MS requirements.\n* Cohort 1: active SPMS; Cohort 2: PPMS or non-active SPMS.\n* Inadequate response to at least one prior high-efficacy disease-modifying therapy administered for at least 6 months.\n* Documented disability progression over the prior 24 months.\n* EDSS 3.0 to 6.5, inclusive.\n* Meets protocol-defined disease-duration, CSF, organ-function, cardiac\u002Fpulmonary, pregnancy testing, contraception, vaccination, and cellular-therapy follow-up requirements.\n\nKey Exclusion Criteria\n\n* RRMS, clinically isolated syndrome, radiologically isolated syndrome, or another diagnosis better explaining the neurologic course.\n* Alternative inflammatory demyelinating disorders, including AQP4-antibody-positive NMOSD and MOG-antibody-associated disease.\n* Active or chronic infection requiring antibiotics, or protocol-specified positive infectious disease testing.\n* Inadequate washout from prior MS therapy or specified recent immunomodulatory treatments.\n* Prior CAR T-cell therapy, other genetically modified immune cell therapy, or gene therapy.\n* Pregnant or breastfeeding, or planning pregnancy during the protocol-defined follow-up period.\n* Specified major cardiovascular, neurologic, transplant, malignancy, bleeding\u002Fthromboembolic, allergy, or protocol-compliance exclusions.","ALL","18 Years","55 Years",{"count":20,"type":21},119,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","This is a global, multicenter, Phase 1b\u002F2 study evaluating the safety and efficacy of C-CAR168, an autologous anti-CD20\u002FBCMA chimeric antigen receptor T-cell therapy, in participants with progressive multiple sclerosis refractory to standard-of-care therapy. The study includes participants with secondary progressive multiple sclerosis (SPMS) and primary progressive multiple sclerosis (PPMS).",[28,29,30,31,32,33,34,35,36],"Multiple Sclerosis","Primary Progressive Multiple Sclerosis","Secondary Progress Multiple Sclerosis (SPMS)","Primary Progressive Multiple Sclerosis (PPMS)","MS","MS (Multiple Sclerosis)","Neuro-Degenerative Disease","Neuro-Degenerative Diseases","Autoimmune",[38,39,40,41,42,43,44,45,29,46,47,48,36,49,50,51],"Progressive Multiple Sclerosis","SPMS","PPMS","CAR T-Cell Therapy","C-CAR168","CD20","BCMA","Secondary Progressive Multiple Sclerosis","CAR-T","CAR T cell","CAR T","neurodegenerative","chimeric antigen receptor T cell","Refractory","NOT_YET_RECRUITING","2026-10-07",{"date":55,"type":56},"2026-10-13","ACTUAL",{"date":58,"type":21},"2027-02",{"date":60,"type":21},"2030-02",{"name":62,"class":63},"AbelZeta Inc.","INDUSTRY",2,{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":72,"targetDuration":4,"studyType":22,"phases":74,"briefSummary":76,"conditions":77,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100604049","early-phase-1-a-study-to-evaluate-the-safety-tolerability-and-preliminary-efficacy-of-neuk203-215-injection-in-adult-chinese-patients-with-relapsedrefractory-autoimmune-diseases-100604049","NCT07144462","A Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of NEUK203-215 Injection in Adult Chinese Patients With Relapsed\u002FRefractory Autoimmune Diseases","Inclusion Criteria:\n\n* 1\\) Has provided signed informed consent; 2) Is aged 18-65 years ; 3)Adequate functional reserve of vital organs 4) Has a confirmed diagnosis of systemic lupus erythematosus, diffuse systemic sclerosis, inflammatory myopathy, or autoimmune bullous dermatosis.\n\nExclusion Criteria:\n\n* 1\\) Requires dialysis treatment. 2) History of severe drug hypersensitivity. 3) Active infection requiring systemic therapy or suspected uncontrolled infection.\n\n  4\\) Within 6 months before screening, any of the following cardiovascular events: New York Heart Association (NYHA) Class III or IV heart failure, myocardial infarction, unstable angina, uncontrolled or symptomatic atrial arrhythmia, any ventricular arrhythmia, or other clinically significant cardiac disease.\n\n  5\\) Malignancy within the past 5 years. 6) Clinically significant chronic or intermittent bleeding within 60 days before the screening visit.\n\n  7\\) Prior solid-organ (e.g., heart, lung, kidney, liver) or hematopoietic stem-cell\u002Fbone-marrow transplantation.\n\n  8\\) At screening: positive HBsAg and\u002For HBcAb with HBV DNA detectable or above the lower limit of quantitation; positive HCV antibody with HCV RNA detectable or above the lower limit of quantitation; positive HIV antibody; positive syphilis test (except biologic false-positive results).\n\n  9\\) Major surgery within 4 weeks before screening. 10) Live or live-attenuated vaccine received within 4 weeks before screening. 11) Uncontrolled concurrent medical conditions. 12) Documented history of neurologic or psychiatric disorders. 13) Any other factor that, in the investigator's judgment, could require premature withdrawal from the study.","65 Years",{"count":73,"type":21},8,[75],"EARLY_PHASE1","The purpose of this study is to determine the safety, tolerability and preliminary efficacy of NEUK203-215 , a healthy donor (HD) allogeneic CD19\u002FBCMA-targeted CAR-NK cell product, in participants with severe, refractory autoimmune diseases.\n\nThis study plans to conduct an interim data analysis when the cumulative enrollment reaches 50% of the total sample size. The objectives of this analysis are: (1) to summarize the safety and tolerability profile at the current dose level; (2) to preliminarily assess trends in clinical response endpoints and explore preliminary signals of drug efficacy; and (3) to preliminarily evaluate the pharmacokinetic and pharmacodynamic characteristics of the drug in humans. This analysis is exploratory in nature and is intended to accumulate preliminary clinical evidence for the drug in the target patient population.",[36],"RECRUITING","2026-07-13",{"date":81,"type":56},"2026-07-15",{"date":83,"type":56},"2025-09-04",{"date":85,"type":21},"2027-01-14",{"name":87,"class":63},"Neukio Biotherapeutics (Shanghai) Co., Ltd.",1,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":96,"sex":16,"minAge":17,"maxAge":71,"enrollmentInfo":97,"targetDuration":4,"studyType":22,"phases":99,"briefSummary":100,"conditions":101,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":103,"startDateStruct":105,"completionDateStruct":107,"leadSponsor":109,"locationsCount":88},"100615339","early-phase-1-study-of-janx011-in-healthy-adult-volunteers-to-assess-safety-and-tolerability-100615339","NCT07291323","Study of JANX011 in Healthy Adult Volunteers to Assess Safety and Tolerability.","A Phase 1, Open-Label Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Ascending Doses of JANX011 With Optional Step-Up Dosing in Healthy Adult Volunteers","Inclusion Criteria:\n\n* Healthy men and women, in the opinion of the PI or designee and as determined by physical examination, laboratory screening tests, and medical history.\n* Aged 18 to 65 years, with a body weight between 50 to 120 kg and a body mass index (BMI) between 18 to 32 kg\u002Fm2 (all inclusive) at Screening.\n* Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.\n\nExclusion Criteria:\n\n* Recent surgery requiring general anesthesia within 12 weeks prior to Screening or is expected to have surgery requiring general anesthesia during the course of the study.\n* Positive test for hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg), human immunodeficiency virus 1 (HIV-1) or HIV-2 antibodies.\n* Positive test for tuberculosis (TB) or history of TB (including prior positive interferon gold test result).\n* Use of any investigational medical device or investigational drug within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to dosing on Day 1.",true,{"count":98,"type":21},60,[75],"This first-in-human (FIH) study aims to characterize the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of JANX011 dosed subcutaneously (and potentially intravenously) in healthy adult volunteers (HVs) to gain insight into its therapeutic utility in patients with autoimmune diseases.",[36],"2026-04-20",{"date":104,"type":56},"2026-04-23",{"date":106,"type":56},"2026-02-16",{"date":108,"type":21},"2026-12",{"name":110,"class":63},"Janux Therapeutics",{"id":112,"slug":113,"hasResults":11,"nctId":114,"briefTitle":115,"officialTitle":116,"acronym":117,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":22,"phases":121,"briefSummary":123,"conditions":124,"keywords":4,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":102,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":135},"100297555","phase-4-taper-or-abrupt-steroid-stop-toassttrial-100297555","NCT03153527","Taper Or Abrupt Steroid Stop: TOASSTtrial","Glucocorticoid Withdrawal and Glucocorticoid-induced Adrenal Insufficiency: a Randomized Controlled Multicenter Trial","TOASST","Inclusion Criteria:\n\n* Informed Consent as documented by signature (Appendix Informed Consent Form)\n* Age ≥ 18 years\n* Daily glucocorticoid dose ≥ 7.5 mg prednisone-equivalent at the time of inclusion\n* Therapy over ≥ 28 days, ≥ 7.5 mg average daily dose, with a cumulative glucocorticoid dose ≥ 420 mg prednisone-equivalent prior to inclusion\n* Tapering not or no longer mandatory to treat underlying disease\n\nExclusion Criteria:\n\n* Primary adrenal failure\n* Treatment with systemic depot glucocorticoids (e.g. intramuscular, epidural)\n* Incapability to administer glucocorticoid cover treatment in situations of stress\n* Inability or unwillingness to provide informed consent\n* Women who are pregnant or breast feeding,\n* Intention to become pregnant during the course of the study,\n* Lack of safe contraception, defined as: Female participants of childbearing potential, not using and not willing to continue using a medically reliable method of contraception for the entire study duration, such as oral, injectable, or implantable contraceptives, or intrauterine contraceptive devices, or who are not using any other method considered sufficiently reliable by the investigator in individual cases.\n* Known or suspected non-compliance\n* Inability to follow the procedures of the study, e.g. due to language problems, psychological disorders, dementia, etc. of the participant,\n* Participation in another study with investigational drug within the 30 days preceding and during the present study,\n* Previous enrolment into the current study,\n* Enrolment of the investigator, his\u002Fher family members, employees and other dependent persons",{"count":120,"type":21},530,[122],"PHASE4","This study is an Investigator-initiated, placebo-controlled, multicenter noninferiority trial, comparing rapid termination of systemic glucocorticoid treatment with a tapering regime over 4 weeks.",[125,36],"Inflammatory Disorder",{"date":127,"type":56},"2026-04-22",{"date":129,"type":56},"2017-05-31",{"date":131,"type":21},"2027-06",{"name":133,"class":134},"University Hospital, Basel, Switzerland","OTHER",16,{"id":137,"slug":138,"hasResults":11,"nctId":139,"briefTitle":140,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":142,"targetDuration":4,"studyType":22,"phases":144,"briefSummary":145,"conditions":146,"keywords":153,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":174,"locationsCount":176},"100564264","phase-1-a-phase-1-study-of-anitocabtagene-autoleucel-for-the-treatment-of-subjects-with-non-oncology-plasma-cell-related-diseases-100564264","NCT06626919","A Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Subjects With Non-oncology Plasma Cell-related Diseases","Inclusion Criteria:\n\n* Subject must be 18 years of age or older\n* Must have MGFA clinical classification Grades 2-4A at time of screening\n* Subject must have clinically active disease and requiring ongoing therapy for GMG\n* MG-ADL score 6 and QMG score \\>10 at screening\n* GMG specific autoantibodies must be above the reference laboratory ULN\n\nExclusion Criteria:\n\n* Subject is pregnant or breastfeeding\n* Treatment with Anti-CD20 agents, calcineurin inhibitors, FcRN inhibitors, azathioprine, mycophenolate mofetil, methotrexate, or cyclophosphamide within the specified time frame prior to leukapheresis or prior to anito-cel infusion\n* Previous treatment with any gene therapy, chimeric antigen receptor therapy or T cell engager\n* Previous thymectomy within 6 months of screening\n* Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator",{"count":143,"type":21},30,[24],"A Phase 1 dose-escalation study designed to evaluate the safety, tolerability, and preliminary efficacy of anito-cel in subjects with generalized myasthenia gravis (GMG). Anitocabtagene autoleucel (anito-cel) is a BCMA-directed CAR-T cell therapy.",[147,148,36,149,150,151,152],"Muscular Diseases","Neuromuscular Manifestations","Autoimmune Diseases","Autoimmune Diseases of the Nervous System","Myasthenia Gravis","Muscle Weakness",[154,155,46,44,156,157,158,159,151,160,161,162,163,164,165,166],"ARC-311","CART","Anito-cel","Generalized Myasthenia Gravis","gMG","MG","non-oncology plasma cell","autoimmune","auto-antibody","chimeric antigen receptor","D-Domain chimeric antigen receptor","B-cell maturation antigen (BCMA)","anitocabtagene autoleucel","2026-02-24",{"date":169,"type":56},"2026-02-25",{"date":171,"type":56},"2025-04-30",{"date":173,"type":21},"2028-04",{"name":175,"class":63},"Arcellx, Inc.",13,{"id":178,"slug":179,"hasResults":11,"nctId":180,"briefTitle":181,"officialTitle":182,"acronym":183,"eligibilityCriteria":184,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":185,"enrollmentInfo":186,"targetDuration":4,"studyType":188,"phases":4,"briefSummary":189,"conditions":190,"keywords":195,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":88},"100492823","7-tesla-mri-brain-imaging-to-decipher-filgotinibs-mode-of-analgesic-action-in-rheumatoid-arthritis-100492823","NCT05697159","7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis","Exploiting Leading Edge 7 Tesla MRI Brain Imaging to Decipher Filgotinib's Mode of Analgesic Action in Rheumatoid Arthritis","TEMPO","Inclusion Criteria:\n\nPatients with moderate to severe active RA who have been prescribed filgotinib in line with the Summary of Product Characterisation and are:\n\n* Adults ≥18 years \\\u003C 75 years.\n* Right-handed (to reduce neuroimaging heterogeneity).\n\nExclusion Criteria:\n\n* Inability to provide written informed consent.\n* Severe physical impairment (e.g. blindness, deafness, paraplegia).\n* Pregnant or breast feeding.\n* Severe claustrophobia precluding MRI.\n* Contraindications to MRI.\n* Major confounding neurological disease including MS, Stroke, Traumatic Brain Injury.\n* Previous targeted synthetic (e.g. baricitinib, tofacitinib) DMARD exposure for RA.","74 Years",{"count":187,"type":21},20,"OBSERVATIONAL","This is an experimental medicine, single-centre, observational test-retest study to evaluate Filgotinib's mechanism of analgesic action in RA patients.\n\nThe investigators hypothesize that Filgotinib's mechanism of analgesic action is determined by at least two factors. The first is related to those CNS sensitization pathways seen in fibromyalgia, specifically DMN-insula brain functional connectivity and insular glutamate.\n\nThe second is related to peripheral inflammation, specifically joint synovitis, blood cytokines\u002Fchemokines and DAN-LIPL functional brain connectivity. The CNS sensitization pain pathways related to fibromyalgia are more quickly modified compared to those related to peripheral inflammation and help explain Filgotinib's rapid onset of effect.",[191,192,193,36,194],"Rheumatoid Arthritis","Sickness Behavior","Inflammatory Disease","Pain, Chronic",[196,197],"Chronic pain","Rhuematoid arthritis","2025-01-13",{"date":200,"type":56},"2025-01-14",{"date":202,"type":56},"2023-08-22",{"date":204,"type":21},"2025-10-31",{"name":206,"class":134},"NHS Greater Glasgow and Clyde"]